The NEMO trial exhibited that advanced NRAS-mutant melanoma patients receiving binimetinib had a median progression-free survival of 28 months while advanced NRAS-mutant melanoma patients receiving dacarbazine had a median progression-free survival of 15 months after a median follow-up of 1.7 months (36). This evidence concerns the gene NRAS and melanoma.